194918-76-8

ACPT-I is an agonist of the group III metabotropic glutamate receptors (mGluRs) mGluR4a and mGluR8 (EC₅₀s = 7.2 and 8.2 μM, respectively) that has no effect on mGluR1a or mGluR2. It has diverse biological activity, including neuroprotective, anticonvulsant, and anxiolytic-like effects. ACPT-I (1-200 μM) reduces cell death following oxygen-glucose deprivation in primary neuronal cultures and in a rat model of middle cerebral artery occlusion when used at a dose of 30 mg/kg. It is neuroprotective against excitotoxicity induced by kainite in vitro and in vivo and reduces the incidence of clonic seizures in various seizure models in mice and rats (ED₅₀s = 0.08-49.3 nM, i.c.v.). ACPT-I also has anxiolytic-like effects in mice and rats, however, these effects can be blocked by WAY-100635 and flumazenil , indicating the involvement of the serotonin (5-HT) receptor subtype 5-HT_1A and GABA_A receptor.

ACPT-I is a competitive antagonist for metabotropic receptors (mGluRs).

Agonist for group III mGlu receptors (EC 50 values are 7.2 and 8.2 μ M for mGlu 4a and mGlu 8 respectively). Anticonvulsant in mice.

Desiccate at -20°C